FLT3 and acute myeloid leukemia: Responses were seen in all of four FLT3-mutant relapsed/refractory AML patients in a small phase 1 (Fiedler et al., 2005), and a phase 1/2 elderly first-line combination study, combined with standard chemotherapy followed by 2 years sunitinib maintenance, reported historically favorable CR rate (59%) and survival outcomes (median overall survival 1.6 years) (Fiedler et al., 2015).